Allergic Conjunctivitis - Epidemiology Forecast to 2023, New Report Launched

Allergic conjunctivitis is an inflammation of the eye resulting from an allergic reaction to allergy causing substances (external antigens) like pollen, dander, mold, or other substances. In allergic conjunctivitis, the conjunctiva - a layer of tissue which lines the front part of the eyeball (the white part of the eye) and the inside of the eyelids are inflammed secondary to an immune response to allergens (Medline Plus, 2014). Allergic conjunctivitis could be categorized as seasonal allergic conjunctivitis (SAC), which is the most common one, perennial allergic conjunctivitis (PAC), giant papillary conjunctivitis (GPC), vernal keratoconjunctivitis (VKC), and atopic keratoconjunctivitis (AKC) (Calonge, 1999). SAC and PAC represent the majority of diagnoses; whereas, AKC, VKC and GPC are relatively rare (Ono and Abelson, 2005).

Allergic conjunctivitis is one of the most common eye problems encountered in general ophthalmic practices. The condition is more prevalent in warm climatic conditions and among Afro-Caribbeans, Arabs, and Asians and less frequent among the White populations. Older population-based studies estimated allergic conjunctivitis prevalence of 15–20%; however, more recent studies show allergic conjunctivitis prevalence as high as 40% in adults ages 15 years and older (Bogacka, 2003; Singh et al., 2010). Furthermore, research suggests that allergic conjunctivitis is often under-diagnosed and consequently under-treated except when it is severe.

This report provides an overview of the risk factors, comorbidities, and global and historical trends for allergic conjunctivitis in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the total one-year prevalent cases of allergic conjunctivitis segmented by sex and age (0–14 years, 15–34 years, 35–54 years, 55–74 years, and ≥75 years) in these markets.

Publisher epidemiologists forecast that the total prevalent cases of allergic conjunctivitis in the 6MM will grow by 5.40% over the next decade, from 155,455,174 total prevalent cases in 2013 to 163,925,356 total prevalent cases in 2023, with almost 50% of the total prevalent cases occurring in the US alone. The increase in the number of total prevalent cases of allergic conjunctivitis in the 6MM can be attributed to changing population demographics in the respective markets. However, further epidemiological research is warranted given that there is a paucity of national and international data evaluating the prevalence of allergic conjunctivitis worldwide. There is also a need to clearly demarcate the allergic conjunctivitis population from the overall allergy population, as currently available epidemiological literature suggests a significant overlap in allergy prevalence with other diseases, such as rhinoconjunctivitis.

Know more about this report at – http://mrr.cm/Zzf

Find all Pharma and Healthcare Report at: http://www.marketresearchreports.com/pharma-healthcare